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Abstract
Background: Aseptic meningitis epidemics may pose various health care challenges.
Methods: We describe the German enterovirus meningitis epidemics in the university hospital centers of Düsseldorf,
Cologne and Berlin between January 1st and December 31st, 2013 in order to scrutinize clinical differences from other
aseptic meningitis cases.
Results: A total of 72 enterovirus (EV-positive) meningitis cases were detected in our multicenter cohort, corresponding
to 5.8% of all EV-positive cases which were voluntarily reported within the National Enterovirus surveillance (EVSurv, based
on investigation of patients with suspected aseptic meningitis/encephalitis and/or acute flaccid paralysis) by physicians
within this period of time. Among these 72 patients, 38 (52.8%) were enterovirus positive and typed as echovirus (18
pediatric and 20 adult cases, median age 18.5 years; echovirus 18 (1), echovirus 2 (1), echovirus 30 (31), echovirus 33 (1),
echovirus 9 (4)). At the same time, 45 aseptic meningitis cases in our cohort were excluded to be due to enteroviral
infection (EV-negative). Three EV-negative patients were tested positive for varicella zoster virus (VZV) and 1 EV-negative
patient for herpes simplex virus 2. Hospitalization was significantly longer in EV-negative cases. Cerebrospinal fluid analysis
did not reveal significant differences between the two groups. After discharge, EV-meningitis resulted in significant
burden of sick leave in our pediatric cohort as parents had to care for the children at home.
Conclusions: Voluntary syndromic surveillance, such as provided by the EVSurv in our study may be a valuable tool for
epidemiological research. Our analyses suggest that EV-positive meningitis predominantly affects younger patients and
may be associated with a rather benign clinical course, compared to EV-negative cases.
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Background
Periodic aseptic meningitis epidemics can be a challenge
in patient- and health care. A large retrospective analysis
of a US-American cohort revealed that in 21% of cases
the etiology of aseptic meningitis remains unknown [1].
Aseptic meningitis is defined [2] by an inflammation of
the leptomeninx in which the causative agent cannot be
identified by cerebrospinal fluid culture [3]. Viruses are
the most common causes of this disease [1, 3]. Viral
meningitides are predominantly caused by enteroviruses
[4], which belong to the picornaviridae consisting of
species A-D. The main route of infection is fecal-oral,
but infestation of the respiratory tract and a droplet
infection are also possible. In previous studies, viral
meningitis in adults was rather associated with herpes
simplex and West Nile virus, whereas children were
more likely to be tested positive for enterovirus (EV) [5].
Therefore, multiple studies have been conducted in
order to better understand this phenomenon: A Danish
nation-wide prospective observational study between 1st
of January 2015 and 30th of June 2016 revealed an
unfavorable outcome of viral meningitis in 17% of all
patients [6]. According to a UK study, the infection rates
of viral meningitis are mainly driven by an EV pre-
dominance of echovirus 30 [7].
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EV meningitis epidemics in Shandong (People’s
Republic of China, 2014 [8]) and Finland (2009 and 2010
[9]) and the clinical pattern of viral central nervous
system (CNS) infections in Italy [10] have previously
been characterized: EV-positive patients presented with
fever, nausea and vomiting, were most likely to be
children, and had no clear gender predominance.
The treatment is symptomatic, employing analgetic drugs
and antipyretic therapy to control body temperature.
Pleconaril has been considered as potential specific treat-
ment for EV-associated meningitis. However, it was not
approved, given its just modest efficacy and considerable
side-effect and interaction profile [11, 12]. In particularly
severe cases, administration of immunoglobulins may
positively influence the course of the disease [13].
Cerebrospinal fluid (CSF) and clinical features of EV-
positive meningitis patients in Germany [14] and the differ-
ences in adult and pediatric EV-positive meningitis patients
in Switzerland [15] have already been analyzed, but there is
still a paucity of data describing the differences in EV-
positive meningitis and EV-negative meningitis patients.
Methods
We conducted a retrospective chart review study at the
Departments of Neurology of the Heinrich-Heine
University Düsseldorf, the University Hospital of
Cologne, the Charité – Universitätsmedizin Berlin and
the Department of General Pediatrics, Neonatology and
Pediatric Cardiology of the Heinrich-Heine University
Düsseldorf searching for all patients with aseptic CNS
infection in 2013. The study was approved by the ethics
committee, University of Düsseldorf (registry number
4423). We used ICD-10 codes to identify cases of inter-
est. As such, priority was given to the ICD-10 keys A87
and G02 (Table 1). However, as patient data may not have
been in the categories listed above due to less precise en-
cryption despite manifest illness, a wider query was add-
itionally performed to identify all patient data encoded as
A85-A89 (Other viral encephalitis, not elsewhere classified;
Unspecified viral encephalitis; Viral meningitis; Other viral
infections of central nervous system, not elsewhere classified;
Unspecified viral infection of central nervous system,
Table 1) and G02–05 (Meningitis in other infectious and
parasitic diseases classified elsewhere; Meningitis due to
other and unspecified causes; Encephalitis, myelitis and en-
cephalomyelitis; Encephalitis, myelitis and encephalomyelitis
in diseases classified elsewhere, Table 1). Virological testing
of CSF for enteroviruses was performed in a standardized
manner by the National Reference Laboratory for Poliomy-
elitis and Enteroviruses at the Robert Koch Institute.
Case definition
After the above-mentioned identification of patient
data, the patient records were individually evaluated
to exclusively select cases of aseptic meningitis de-
fined according to the Centers for Disease Control
and Prevention (CDC) [16] as acute onset of menin-
geal symptoms, fever, and cerebrospinal fluid pleocy-
tosis with bacteriologically sterile cultures.
Analysis
The following criteria were investigated for further
analysis: Patient age, time point of manifestation, pre-
hospital time / duration of clinical manifestation before
confirmation of aseptic meningitis by CSF analyses, re-
sults of CSF diagnostics (cell count, protein content),
duration of inpatient stay, type of clinical restitution
(complete restitution vs. persistence of residual symp-
toms), for children treated in Düsseldorf time of incap-
acity for work of parents. CSF cell count and protein
content were measured according to the local laboratory
standard (Düsseldorf: turbidimetric, benzethonium
chloride method, cobas® 8000, C701, Fa. Roche Diagnos-
tics, Mannheim for protein content, mechanized cell
count, UF 1000i, Sysmex for cell count; Berlin: turbidi-
metric assay TPUC3, Roche/Hitachi cobas® c for protein
content, Fuchs-Rosenthal method for cell count;
Cologne: nephelometric assay for protein content,
Fuchs-Rosenthal method for cell count).
In order to put this data in perspective, we performed
a query of the German-wide database of the Robert
Koch Institute (RKI; EVSurv) [17] of all EV-positive
meningitis cases in 2013. Data was obtained in the
context of the National Enterovirussurveillance, which is
based on voluntary reporting and investigation of hospi-
talized patients with suspected aseptic meningitis/en-
cephalitis and/or acute flaccid paralysis. All samples
were tested at the RKI using RT-nested PCR with the
primers targeting the 5′NCR gene, as previously
Table 1 List of ICD-10 codes utilized to identify patients with
aseptic meningitis from the clinical databases of each hospital
participating in this study
ICD-10 Description
A85 Other viral encephalitis, not elsewhere classified
A86 Unspecified viral encephalitis
A87 Viral meningitis
A88 Other viral infections of central nervous system,
not elsewhere classified
A89 Unspecified viral infection of central nervous
system
G02 Meningitis in other infectious and parasitic
diseases classified elsewhere
G03 Meningitis due to other and unspecified causes
G04 Encephalitis, myelitis and encephalomyelitis
G05 Encephalitis, myelitis and encephalomyelitis in
diseases classified elsewhere
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described [18]. All PCR products were sequenced and -
based on the resulting EV species - tested with species-
specific PCR assays in the VP1 region for typing as
recently described [19–21].
Statistical analyses were performed as indicated using
SPSS Version 20 (IBM Corp. NY, USA); non-parametric
testing was performed since all investigated variables
were non-normally distributed (Shapiro-Wilk-test); p
values < 0.05 were considered significant. If not specified
otherwise, data are provided as median (25th; 75th per-
centile). Furthermore, a Chi-Square-test was performed
in order to compare adults with children and a Spear-
man’s correlation was performed in order to explore
predictors of hospitalization. Adjusted p-values (adj. p)
were calculated using Bonferroni correction, values
below 0.05 were considered significant. To enhance
readability of the results section, significant values are
provided in three categories: < 0.05, < 0.01, and < 0.001,
respectively. Finally, a multivariate, stepwise linear re-
gression was performed in order to extract variables of
potential predictive value for the time of hospitalization.
Results
Results of the retrospective analysis in Düsseldorf,
Cologne and Berlin 2013.
We identified 72 EV-positive cases (31 females, 41
males) with a median age of 15 (3.25; 32.75) years.
Among these 72 patients, 38 (52.8%) were echovirus-
positive (18 pediatric and 20 adult cases, median age
18.5 (5.25; 31.25) years; echovirus 18 (1), echovirus 2 (1),
echovirus 30 (31), echovirus 33 (1), echovirus 9 (4)), 1
patient was enterovirus 71 (EV-A71)-positive, 1 patient
was coxsackie A9-positive, 1 patient was enterovirus B-
positive and the specific enterovirus species of the
remaining 31 EV-positive cases remained unknown or
were not further typed, as not enough CSF was available
for further analysis. EV-positive meningitis cases peaked
in July/August (Fig. 1). Furthermore, we identified 45
enterovirus-negative cases (16 females, 29 males, median
age 36 (28; 48.5) years). Among EV-negative cases, three
were related to varicella zoster infection, one to herpes
simplex 2 and no virus could be identified in the other
patients.
Analysis of the CSF parameters cell count (EV-posi-
tive: 81 (12; 205) cells/μl, EV negative 67 (17.5; 185.25)
cells/μl, Fig. 2a) and total protein (EV-positive 0.52
(0.35; 0.68) g/l, EV-negative 0.53 (0.36, 0.78) g/l, Fig. 2b)
in EV-positive and EV-negative patients revealed no
significant difference (Mann-Whitney U test). 2 EV-
positive and 1 EV-negative CSF samples could not be
evaluated due to a blood contamination.
Analysis of the number of nights spent in hospital by
the patients revealed that hospitalization was signifi-
cantly longer in EV-negative (6 (3; 13) nights) than in
EV-positive cases (3 (1; 5) nights, adj. p < 0.01, Mann-
Whitney U test, Fig. 3).
No fatal cases occurred. In children, parents reported
of mild complaints after discharge like headache, back-
ache and fatigue for 0 to 7 days (median 2 days; Düssel-
dorf cohort). After discharge, one of the parents had to
Fig. 1 Monthly distribution of meningitis cases in 2013 (Düsseldorf, Cologne, Berlin). These data were obtained from database query. Enterovirus
(EV)-positive cases peaked from July to August in 2013
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care for the children at home (0 to 5 days, median 3
days; Düsseldorf cohort).
Analysis of gender (Chi-Square-test of EV-positive vs.
EV-negative patients, adults vs. children and hospitalization
periods) did not reveal relevant differences.
Adults vs. children
A significantly higher ratio of children was found in the
enterovirus-positive cohort, compared to the enterovirus
negative group (38/72 vs. 4/45, Chi-Square-test, adj.
p < 0.001). Children (both EV-positive and EV-negative)
had a shorter period of hospitalization (adj. p < 0.001) and
lower CSF protein levels than adults (adj. p < 0.001). There
was no significant difference of CSF cell counts
(Mann-Whitney U test, respectively).
An exclusive analysis of either adults or children did
not reveal significant differences between EV-positive
and EV-negative patients regarding age, duration of
inpatient stay, CSF cell count and CSF total protein
(Mann-Whitney U test, respectively). Numerical data of
abovementioned comparisons are provided in Table 2.
Predictors of hospitalization periods
In general, the duration of inpatient stay correlated with
age (Spearman’s Rho correlation coefficient 0.418,
p < 0.001), CSF total protein (Spearman’s Rho correlation
coefficient 0.319, p < 0.001), and the delay from symptom
onset to lumbar puncture (Spearman’s Rho correlation
coefficient 0.232, p = 0.023). For nominal variables, entero-
virus status (η = − 0,32) correlated with the duration of
inpatient stay. In contrast, echovirus status, gender, and
location (Neurological center the patient was treated) did
not show a relevant correlation with the duration of the
inpatient stay (| η | < 0,3).
Finally, a multivariate, stepwise linear regression was
performed using the abovementioned variables (age, CSF
cell count, CSF protein, delay between symptom onset
and spinal tap enterovirus status, echovirus status,
gender, treating center (Berlin, Cologne, Duesseldorf)).
A total of three variables (age, CSF protein, and Echo-
virus status) were kept, which accounted for 30% of the
variance of the hospitalization period (adjusted R2 =
0.302, standardized Beta values: age = 0.354, CSF protein
0.247, and echovirus status − 0.169, respectively).
Therapy
The cases diagnosed with varicella zoster virus and
herpes simplex virus 2 received specific therapy. No
child received specific therapy in Düsseldorf.
RKI database query
An RKI database query (retrieved from https://evsurv.
rki.de/) revealed a total of 3455 tested samples in 2013.
1242 of these cases were positive for EV, of which 672
cases were typed as echovirus 30. Therefore, our study
includes 5.8% (72 of 1242 cases) of the reported EV-
positive cases in Germany.
Fig. 2 Cerebrospinal fluid analysis of enterovirus (EV)-positive and EV-negative patients. No significant difference in cell count (a) and total protein
(b). CSF = cerebrospinal fluid. Mann-Whitney U test
Fig. 3 Hospitalization analysis of enterovirus (EV)-positive (n = 72)
and EV-negative patients (n = 45). Hospitalization of EV-negative
patients is significantly longer (p < 0.01). Mann-Whitney U test
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Discussion
Enteroviruses are highly neurotropic and can manifest as
meningitis, meningoencephalitis, poliomyelitis-like an-
terior myelitis, and Guillain-Barré syndrome [22, 23]. In
our cohort, enteroviral infections were associated with
meningitis. The prevalence of enteroviral meningitis is
high worldwide (estimated 75,000 cases annually in the
United States) [11], which makes this type of meningitis
highly relevant to both caregivers and patients. We were
able to show that the rate of infection peaks in the sum-
mer and early autumn months (June, July and August;
Fig. 1). With age, the incidence of enteroviral meningitis
decreases. Therefore, the incidence is highest in infants
and toddlers [24], which was also the case in our cohort
(Table 2).
The following findings and assumptions of our study
are of significant interest, as they stress differences be-
tween EV-positive and EV-negative meningitis and may
be of relevance for the treating physician: Overall,
caregivers may expect shorter hospitalization times in
EV-positive meningitis cases. Furthermore, routine CSF
parameters that may already be determined in the emer-
gency unit are not a sufficient tool to discriminate
between EV-positive and EV-negative meningitis. When
caregivers experience an unusual accumulation of asep-
tic meningitis cases in the summer and early autumn,
patients should be tested for enterovirus infections and
cases should be reported to the authorities. Contrary to
previous studies regarding viral meningitis in general
our data show that EV-positive meningitis is rather
associated with a benign disease course.
In adult patients, the disease generally necessitates
inpatient treatment for several days [25]. When children
are affected, one parent may be incapacitated for a cer-
tain period of time to care for the child. In both cases,
the disease may be associated with a temporary inability
to work (either patient or parent). Because of the high
number of cases per year, considerable costs arise for
Table 2 Distribution of age, hospitalization, CSF cell count, and CSF protein for EV negative, EV positive, and all patients (Total). All
groups are further subdivided by age into adults (ADU), children (PED), and all (Total) patients. N = number of patients, 75th perc. =
75th percentile, 25th perc = 25th percentile
EV negative EV positive Total
ADU PED Total ADU PED Total ADU PED Total
Age (years)
N 41 4 45 34 38 72 75 42 117
Range 64 10 77 56 17 74 66 17 84
75th perc. 50 14.75 48.5 40 9 32.75 44 9 38
median 36 8 36 33.5 5 15 36 6 26
25th perc. 30 7.25 28 24 0 3.25 27 0.75 8
Hospitalization (nights)
N 41 4 45 34 38 72 75 42 117
Range 35.00 5 35 31.00 9.00 31 36.00 9.00 36
75th perc. 13 5 13 6 3.25 5 10 3.25 7
median 6 2 6 4 2.00 3 5 2 4
25th perc. 3.5 1.25 3 1.75 1 1 2 1 2
CSF cell count (cells/μl)
N 40 4 44 34 36 70 74 40 114
Range 1255 100 1255 744 877 877 1255 877 1255
75th perc. 202.25 129.75 185.25 314.75 142 205 275.75 132.25 196.5
median 61.5 100 67 114.5 24.5 81 88 34.5 78
25th perc. 15.25 44.75 17.50 40.5 6.75 12 23.75 9.5 15
CSF protein (g/l)
N 40 4 44 34 36 70 74 40 114
Range 1.30 0.64 1.30 1.29 0.73 1.51 1.66 0.73 1.65
75th perc. 0.78 0.79 0.78 0.80 0.57 0.68 0.78 0.58 0.74
median 0.53 0.42 0.53 0.65 0.34 0.52 0.56 0.36 0.52
25th perc. 0.39 0.23 0.36 0.48 0.25 0.35 0.43 0.250 0.36
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society due to the loss of work and the necessary re-
sources for medical treatment [26], although meningitis
caused by enteroviruses usually has a relatively benign
course.
To the best of our knowledge, the economic burden
for society due to EV-positive meningitis has not been
determined so far; and our data also provide just a lim-
ited insight, since we analyzed the duration of inpatient
stay but did not assess any further inability to work.
Our data indicate that the course of EV-positive men-
ingitis is predominantly benign, and that hospitalization
time was significantly shorter in EV-positive, compared
to EV-negative cases. This was also the case, when we
did not consider the above-mentioned meningitis cases
that received specific antiviral therapy (varicella zoster
virus, herpes simplex virus 2). Moreover, a higher ratio
of affected children and young adults were found in EV-
positive cases. This could be explained by affected
parents of young, diseased children. Hence, earlier con-
valescence in EV-positive groups may be explained by
differences of age between both groups rather than dif-
ferent courses of the disease in general. In our cohort,
routine CSF analysis (pleocytosis, protein level) is not a
useful tool to discriminate between EV-positive and
negative cases, but CSF protein level may correlate with
length of stay in hospital.
Despite the generally excellent outcome of aseptic
meningitis, there are rare instances of complicated
courses that may lead to persistent neurological disabil-
ity or even death [27–30]. Strategies for the systematic
containment of endemic diseases are focused on ensur-
ing hygienic measures to prevent the spread of viruses,
as some weeks after illness, virulent pathogens can still
be excreted via the feces.
In agreement with previous studies, enterovirus infec-
tions were detected as the most common cause for an
aseptic meningitis in our cohort, driven by a high preva-
lence of echoviruses (52,8%). Indeed, our study demon-
strates that voluntary reporting of diseases such as in
this case can be an effective tool to better understand
epidemiological details of certain diseases:
The mean age of EV-positive patients in our centers
was 15 (3.25; 32.75) years, which accurately fits to previ-
ous data of Shandong [8] and Finland [9] (Finland 2009
15 years 8 months, Finland 2010 17 years 6 months,
Shandong 2014 children within 15 years of age). The
mean age of EV-negative pediatric patients (8 (7.25;
14.75) years) in our cohort was quite similar to that in a
large South Korean pediatric cohort (8.4 ± 5 years) [31].
Conclusions
EV-positive epidemics are similar in terms of age and
gender distribution and other factors worldwide. Overall,
this entity remains a rather benign form of meningitis
with a rather short length of stay in hospital, but may be
associated with complicated courses that may lead to
persistent neurological disability or even death. Routine
CSF testing (pleocytosis, protein level) may not be suit-
able to distinguish EV-positive and EV-negative cases,
but CSF protein level may correlate with hospitalization.
Still, epidemics are a challenge for the health care
system. Therefore, we recommend rigorous testing and
reporting of aseptic meningitis cases. Within the
National Enterovirussurveillance (EVSurv) all pediatric
and neurological hospitals in Germany are offered free-
of-charge enterovirus diagnostics in patients with sus-
pected aseptic meningitis / encephalitis or acute flaccid
paralysis. This health care concept is also well estab-
lished in the US and led to a concise description of the
disease burden [32].
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